Global $41 Bn Respiratory Drugs Market to 2023 - Leading Players are GSK, AstraZeneca and Boehringer Ingelheim

DUBLIN, October 12, 2017 /PRNewswire/ --

The "Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers" report has been added to Research and Markets' offering.

Global revenue from the respiratory market is forecast to increase from $30.9 billion in 2016 to $41.3 billion in 2023, at a compound annual growth rate of 4.23%.

Recently approved products in COPD include multiple LABA/LAMA fixed-dose combinations, some of which are forecast to generate over $1 billion by 2023, and include GlaxoSmithKline (GSK)'s triple-combination therapy (fluticasone furoate plus umeclidinium bromide plus vilanterol trifenatate).

The approval of novel biologics in the asthma market, including interleukin (IL)-targeting Nucala (mepolizumab), marketed by GSK, is also forecast to have a strong commercial impact on the market. Notable drivers of growth in the cystic fibrosis (CF) market are the recently approved disease-modifying therapies Kalydeco (ivacaftor) and Orkambi (lumacaftor/ivacaftor), both from Vertex.

Respiratory therapy area consists of indications that affect the lungs, bronchi, trachea, larynx, pharynx and nose in different ways, such as the scarring of lung tissue or the excessive production of mucus. Respiratory disease most commonly results in breathing difficulties, which can lead to disruptions in sleep, wheezing, anxiety and stress. In more severe cases shortness of breath (dyspnea) can limit physical activity, affecting both the quality of life and life expectancy of sufferers. The cause of respiratory disorders varies significantly across each indication and includes factors such as environment, occupation, genetic predisposition and aging.

In 2016, GSK was the leading company in terms of revenue generated from respiratory disorder products, accounting for 30.3% of the market, while Vertex had a small market share of 5.3%. However, the emergence of cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapies, which are considered disease-modifying therapies for CF, an indication which has traditionally only had symptomatic treatments, is set to have a substantial clinical and commercial impact. There are only two of these products on the market, Orkambi and Kalydeco, both of which were developed by Vertex.

Key Topics Covered:

1 Table of Contents

2 Introduction
2.1 Therapy Area Introduction
2.2 Symptoms
2.3 Diagnosis
2.3.1 Asthma
2.3.2 Chronic Obstructive Pulmonary Disease
2.3.3 Idiopathic Pulmonary Fibrosis
2.3.4 Cystic Fibrosis
2.4 Etiology and Pathophysiology
2.4.1 Asthma
2.4.2 Chronic Obstructive Pulmonary Disease
2.4.3 Idiopathic Pulmonary Fibrosis
2.4.4 Cystic Fibrosis
2.5 Epidemiology
2.5.1 Asthma
2.5.2 Chronic Obstructive Pulmonary Disease
2.5.3 Idiopathic Pulmonary Fibrosis
2.5.4 Cystic Fibrosis
2.6 Prognosis and Disease Staging
2.6.1 Asthma
2.6.2 Chronic Obstructive Pulmonary Disease
2.6.3 Idiopathic Pulmonary Fibrosis
2.6.4 Cystic Fibrosis
2.7 Treatment
2.7.1 Asthma
2.7.2 Chronic Obstructive Pulmonary Disease
2.7.3 Idiopathic Pulmonary Fibrosis
2.7.4 Cystic Fibrosis

3 Key Marketed Products
3.1 Overview
3.2 Advair - GSK
3.3 Symbicort - AstraZeneca/Astellas
3.4 Spiriva - Boehringer Ingelheim
3.5 Xolair - Roche/Novartis
3.6 Ventolin - GSK
3.7 Pulmicort - Astra Zeneca
3.8 Orkambi - Vertex
3.9 Relvar/Breo Ellipta - GSK
3.10 Singulair - Merck & Co.
3.11 Esbriet - Roche
3.12 Kalydeco - Vertex
3.13 Conclusion

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.5 Assessment of Key Pipeline Products
4.5.1 Ivacaftor and Tezacaftor - Vertex
4.5.2 (Fluticasone Furoate plus Umeclidinium Bromide plus Vilanterol Trifenatate) - GlaxoSmithKline/Innoviva
4.5.3 Dupixent - Regeneron Pharmaceuticals/Sanofi
4.5.4 Benralizumab - AstraZeneca/Medimmune
4.5.5 Tralokinumab - AstraZeneca
4.5.6 PT010 (Budesonide plus Formoterol Fumarate plus Glycopyrrolate) - AstraZeneca/Pearl Therapeutics
4.5.7 Conclusion
4.6 Conclusion

5 Multi-scenario Market Forecast to 2023
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 G Protein-Coupled Receptors
5.3.2 Immune/Inflammatory Mediators
5.3.3 Transcription Factors
5.3.4 Signal Transduction
5.3.5 CFTR Modulator

6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 GlaxoSmithKline
6.1.2 Vertex
6.1.3 AstraZeneca
6.1.4 Roche
6.1.5 Boehringer Ingelheim
6.1.6 Novartis
6.1.7 Teva
6.1.8 Sumitomo Dainippon
6.1.9 Regeneron
6.1.10 Merck & Co.
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deal by Region, Year and Value
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type and Molecular Target
7.1.4 Table for Licensing Deals Valued Above $100m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type, Mechanism of Action and Value
7.2.4 Table for Co-development Deals Valued Above $100m

8 Appendix
8.1 Bibliography
8.2 All Pipeline Drugs by Phase
8.2.1 Discovery
8.2.2 Preclinical
8.2.3 IND/CTA-Filed/Phase 0
8.2.4 Phase I
8.2.5 Phase II
8.2.6 Phase III
8.2.7 Pre-registration
8.3 Abbreviations
8.4 Methodology

Companies Mentioned

• Astra Zeneca
• Astellas
• Boehringer Ingelheim
• GlaxoSmithKline
• Merck & Co.
• Novartis
• Regeneron
• Roche
• Sumitomo Dainippon
• Teva
• Vertex

For more information about this report visit https://www.researchandmarkets.com/research/jwb4rr/global

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[e-mail]

For E.S.T Office Hours Call [phone]
For U.S./CAN Toll Free Call [phone]
For GMT Office Hours Call [phone]

U.S. Fax: [phone]
Fax (outside U.S.): [phone]